에서 실시간으로 운영 중이에요! 자세히 알아보기

GMDA

Gamida Cell Ltd. Ordinary Shares

GMDA

시가총액 US$504만

상장 폐지됨

GMDA은(는) 2024년 4월 5일에 상장 폐지됐어요.

순위로 돌아가기

소개: Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.

직원 수: 148

건강관리 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

Why Is Gamida Cell (GMDA) Stock Down 82% Today?

Gamida Cell (NASDAQ: GMDA ) stock is falling hard on Wednesday after the clinical-stage biopharmaceutical company announced major changes to its business in its Q4 earnings report. This big news here is the company entering into a Restructuring Support Agreement (RSA) with funds managed by Highbridge Capital Management.

Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript

Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge ® (omidubicel-onlv)

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge ® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding Company to host conference call today at 8:30 a.m. ET BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd.

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.

Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel-onlv)

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Gamida Cell Actively Pursuing Strategic Alternatives

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction. However, there can be no assurance that the company's strategic alternatives process will result in any such transaction.

Gamida Cell Actively Pursuing Strategic Alternatives

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings will take place virtually and in person at the Henry B. González Convention Center in San Antonio, Texas, February 21-24.

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles.

Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.